JY
ALXO icon

Jeff Yass’s ALX Oncology ALXO Stock Holding History

Jeff Yass’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,700
Closed -$39.6K – 13313
2026
Q1 		$39.6K Buy
19,700
+2,100
+12% +$4K ﹤0.01% 12692
2025
Q4 		$19.9K Buy
+17,600
New +$26.6K ﹤0.01% 11962
2025
Q1 		– Sell
-21,800
Closed -$36.4K – 12395
2024
Q4 		$36.4K Buy
21,800
+11,400
+110% +$17.5K ﹤0.01% 11791
2024
Q3 		$18.9K Sell
10,400
-94,600
-90% -$352K ﹤0.01% 11636
2024
Q2 		$633K Buy
105,000
+93,700
+829% +$1.15M ﹤0.01% 7703
2024
Q1 		$126K Sell
11,300
-42,600
-79% -$598K ﹤0.01% 11059
2023
Q4 		$803K Buy
53,900
+41,600
+338% +$395K ﹤0.01% 7528
2023
Q3 		$59K Buy
12,300
+2,100
+21% +$11.4K ﹤0.01% 11218
2023
Q2 		$76.6K Buy
+10,200
New +$66.8K ﹤0.01% 11128
2022
Q2 		– Sell
-21,300
Closed -$360K – 12803
2022
Q1 		$360K Sell
21,300
-2,000
-9% -$34.1K ﹤0.01% 9811
2021
Q4 		$501K Buy
23,300
+6,700
+40% +$289K ﹤0.01% 9211
2021
Q3 		$1.23M Buy
16,600
+8,800
+113% +$587K ﹤0.01% 7021
2021
Q2 		$427K Buy
7,800
+900
+13% +$53.9K ﹤0.01% 9958
2021
Q1 		$509K Buy
6,900
+2,400
+53% +$189K ﹤0.01% 9424
2020
Q4 		$388K Buy
+4,500
New +$271K ﹤0.01% 8793

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Jeff Yass's ALXO Position: Q2 2026 in Review

Jeff Yass reduced its ALX Oncology (ALXO) stake by 91% in Q2 2026, selling an estimated $2.16M and leaving 123,157 shares worth $255K. The position accounts for ﹤0.01% of the portfolio, ranked #11415.

Jeff Yass first reported a position in ALXO in Q4 2020 and has held it in 21 quarters since. The position peaked at $2.66M in Q1 2026. 93 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • Jeff Yass held 123,157 shares of ALX Oncology worth $255K as of Q2 2026.
  • Jeff Yass sold 1,205,750 ALX Oncology shares in Q2 2026, an estimated $2.16M.
  • ALX Oncology made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11415 holding.
  • Jeff Yass first reported a position in ALX Oncology in Q4 2020 and has held it in 21 quarters since.
  • Jeff Yass's ALX Oncology position peaked at $2.66M in Q1 2026.
  • 93 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.